Gene Transfer in the Cardiovascular System Update 2000

Heart Disease

Volumn 2, Issue 6, 2000, Pages 409-421

  Medin, Jeffrey A ^a   Buttrick, Peter M ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Adenovirus; DNA; Gene therapy; Gene transfer

Indexed keywords

CARDIOVASCULAR DISEASE; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; IN VITRO STUDY; REVIEW;

CARDIOVASCULAR DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMAN; IN VITRO;

EID: 0034332591     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (164)

1. Friedmann T. Human gene therapy - an immature genie, bur certainly out of the bottle. Nat Med 1996;2:144-147.
2. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
3. 165 in patient with ischaemic limb. Lancet 1996;348:370-374.
4. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phYEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
5. Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998;2:549-558.
6. Cole-Strauss A, Yoon K, Xiang Y, et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DXA oligonucleotide. Science 1996;273: 1386-1389.
7. Alexcev V, Yoon K. Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide. Nat Biotechnol 1998;16:1343-1346.
8. Miller AD. Human gene therapy comes of age. Nature 1992;357:455-460.
9. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-932.
10. Ledley FD. Non-viral gene therapy. Curr Opin Biotechnol 1994;5:626-636.
11. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995;270:404-410.
12. McLachlan G, Stevenson BJ, Davidson DJ, et al. Bacterial DNA is implicated in the inflamatory response to delivery of DNA/DOTAP to mouse lungs. Gene Ther 2000;7:384-392.
13. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000;7:31-34.
14. Simoes S, Slepushkin V, Gaspar R, et al. Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther 1998;5:955-964.
15. Budker V, Gurevich V, Hagstrom JE, et al. pH sensitive, catoinic liposomes: a new synthetic virus-like vector. Nat Biotechnol 1996;14:760-764.
16. Ross PC, Hui SW. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther 1999;6:651-659.
17. Hodgson CP, Solaiman F. Virosomes: cationic liposomes enhance retroviral transduction. Nat Biotechnol 1996;14:339-342.
18. Schoen P, Chonn A, Cullis PR, et al. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther 1999;6:823-832.
19. Friedmann T. The development of human gene therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999.
20. Uzendoski K, Kantor JA, Abrams SI, et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997;8:851-860.
21. Glorioso JC, DeLuca XA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Ann Rev Microbiol 1995;49: 675-710.
22. Palese P, Zheng H, Engelhardt OG, et al. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA 1996;93:11354 11358.
23. Hewson R. RNA viruses: emerging vectors for vaccination and gene therapy. Mol Med Today 2000;6:28-35.
24. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
25. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998;72:3161-3168.
26. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
27. Burns JC, Friedmann T, Driever W, et al. Vesticular stomatitis virus G glyco protein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993;90:8033-8037.
28. Sakoda T, Kasahara N, Hamamori Y, et al. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999;31:2037-2047.
29. Hanenberg H, Xiao XL, Dilloo D, et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996;2:876-882.
30. Hennemann B, Chuo JY, Schley PD, et al. High-efficiency retroviral transduction of mammalian cells on positively charged surfaces. Hum Gene Ther 2000; 11:43-51.
31. Cosset FL, Takeuchi Y, Battini JL, et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995;69:7430-7436.
32. Mason JM, Guzowski DE, Goodwin LO, et al. Human serum-resistant retroviral vector particles from galactosyl (α1-3) galactosyl containing nonprimate cell lines. Gene Ther 1999;6:1397-1405.
33. Trobridge GD, Russell DW. Helper-free foamy virus vectors. Hum Gene Ther 1998;9:2517-2525.
34. Medin JA, Karlsson S. Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Proc Assoc Am Phys 1997;109:111-119.
35. Pawliuk R, Bachelot T, Wise RJ, et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999;5:768-773.
36. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998;4:1136-1143.
37. Blau CA, Peterson KR, Drachman JG, et al. A proliferation switch for genetically modified cells. Proc Natl Acad Sci USA 1997;94:3076-3081.
38. Jin L, Siritanaratkul N, Emery DW, et al. Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci USA 1998;95:8093-8097.
39. Robbins PB, Skelton DC, Yu XJ, et al. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci USA 1998;95:10182-10187.
40. Wang L, Robbins PB, Carbonaro DA, et al. High-resolution analysis of cytosine methylation in the 5' long terminal repeat of retroviral vectors. Hum Gene Ther 1998;9:2321-2330.
41. Dang Q, Auten J, Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J Virol 2000;74:2671-2678.
42. Newman K, Dunn P, Owens J, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1996;96:2955-2965.
43. Newman S. Virus treatment questioned after gene therapy death. Nature 1999; 401:517-518.
44. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-2245.
45. Warsto RP, Rosenthal ER, Seth PK, et al. Recombinant, replication defective adinovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J Virol 1998;72:9491-9502.
46. Brough DE, Lizonova A, Hsu C, et al. A gene transfer vector cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996;70:6497-6501.
47. Steinwaerder DS, Carlson CA, Lieber A. Generation of adenovirus vectors dovoid of all viral genes by recombination between inverted repeats. J Virol 1999;73:9303-9313.
48. Ghen HH, Mack LM, Kelly R, et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997;94:1645-1650.
49. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93:13565-13570.
50. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region l-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-1917.
51. Sandig V, Youil R, Bett AJ, et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 2000;97:1002-1007.
52. Steinwaerder DS, Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 2000;7:556-567.
53. Chan SY, Li K, Piccotti JR, et al. Tissue-specific consequences of the antiadenoviral immune response: implications for cardiac transplants. Nat Med 1999;10:1143-1149.
54. Donahue BA, McArthur JG, Spratt SK, et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J Gene Med 1999; 1:31-42.
55. Winocour E, Callaham MF, Huberman E. Perturbation of the cell cycle by adeno-associated virus. Virology 1988;167:393-399.
56. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996;93:14082-14087.
57. Herzog RW, Hagstrom JN, Kung S-H, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997;94:5804-5809.
58. Rabinowitz JE, Samulski J. Adeno-associaled virus expression systems for gene transfer. Curr Opin Biotechnol 1998;9:470-475.
59. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000;7:24-30.
60. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-2232.
61. Collaco RF, Cao X, Trempe JP. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999;238:397-405.
62. Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998;72:7024-7031.
63. Lieber A, Steinwaerder DS, Carlson CA, et al. Integrating adenovirus-adenoassociated virus hybrid vectors devoid of all viral genes. J Virol 1999;73:9314-9324.
64. Benedict CA, Tun RYM, Rubinstein DB, et al. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 1999;10:545-557.
65. Hall FI, Gordon EM, Wu L, et al. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther 1997;8:2183-2192.
66. Boerger AL, Snitkovsky S, Young JA. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci USA 1999;96:9867-9872.
67. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann NY Acad Sci 1999;886:158-171.
68. Bartlett JS, Kleinschmidt J, Boucher RC, et al. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody. Nat Biotechnol 1999;17:181-186.
69. Nabel EG, Plautz G, Boyce FM, et al. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989;244:1342-1344.
70. Wilson JM, Birinyi LK, Salomon RN, et al. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989;244:1344-1346.
71. Dicheck D, Neville RF, Zwiebel JA, et al. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989;80:1347-1353.
72. Dhawan J, Pabn LC, Pavlath GK, et al. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 1991;254: 1509-1512.
73. Yao SN, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci USA 1992;89:3357-3361.
74. Hortelano G, Ai-Hendy A, Ofosu FA, et al. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996;87:5095-5103.
75. Soonpa MH, Koh GY, Klug MG, et al. Formation of nascent intercalated disks between grafted fetal cardiocytes and host myocardium. Science 1994;264:98-101.
76. Wolfe JH, Sands MS, Barker JE, et al. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 1992;360:749-753.
77. Takenaka T, Murray GJ, Qin G, et al. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA 2000;97: 7515-7520.
78. Fairbairn LJ, Lashford LS, Spooncer E, et al. Long-term in vitro correction of α-L-iduronidase deficiency (Hurler syndrome) in human bone marrow. Proc Natl Acad Sci USA 1996;93:2025-2030.
79. Takenaka T, Hendrickson CS, Tworek DM, et al. Enzymatic and functional correction along with long term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol 1999;27:1149-1159.
80. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nt Genet 1994;6:335-341.
81. Dunn PF, Newman KD, Jones M, et al. Seeding of vascular grafts with genetically modified endothelial cells: secretion of recombinant tPA results in decreased seeded cell retention in vitro and in vivo. Circulation 1996;93:1439-1446.
82. Feldman LJ, Steg G. Optimal techniques for arterial gene transfer. Cardiovasc Res 1997;35:391-404.
83. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990;249:1285-1288.
84. Mitchel JF, Fram DB, Palme DF, et al. Molecular and cellular cardiology: enhanced intracoronary thrombolysis with urokinase using a novel local drug delivery system: in vitro, in vivo, and clinical studies. Circulation 1995;91:785-793.
85. Tahlil O, Brami M, Feldman LJ, et al. The dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997;33:181-187.
86. Steg PG, Feldman LJ, Scoazec J-Y, et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 1994;90:1648-1656.
87. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990;15:475-481.
88. Feldman LJ, Steg PG, Zheng LP, et al. Low efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerosis rabbit. J Clin Invest 1995;95:2662-2671.
89. Willard JE, Landau C, Glamann B, et al. Genetic modification of the vessel wall: comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation 1994;89:2190-2197.
90. Autieri MV, Yue T, Ferstein GZ, et al. Antisense oligonucleotides to the p65 subunit of NF-κB inhibit humans vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 1995;213:827-836.
91. Sawa Y, Kaneda Y, Bai HZ, et al. Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery. Gene Ther 1998;5:1472-1480.
92. French BA, Mazur W, Geske RS, et al. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circ Res 1994;90: 2414-2424.
93. Magovern CJ, Mack CA, Zhang J, et al. Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg 1996;62:425-433.
94. Tio RA, Tkebuchava T, Scheuermann TH, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999;10:2953-2960.
95. Mason CAE, Bigras J-L, O'Blenes SB, et al. Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation. Nat Med 1999;5:176-182.
96. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000; 7:232-240.
97. Wright MJ, Rosenthal E, Stewart L, et al. β-galactosidase staining following intracoronary infusion of cationic liposomes in the in vivo rabbit heart is produced by microinfarction rather than effective gene transfer: a cautionary tale. Gene Ther 1998;5:301-308.
98. Hughes GC, Annex BH, Yin B, et al. Transmyocardial laser revascularization limits in vivo adenoviral-mediated gene transfer in porcine myocardium. Cardiovasc Res 1999;44:81-90.
99. Libby P. Gene therapy of restenosis: promises and perils. Circ Res 1998;82: 404-406.
100. Simari RD, San H, Rekhter M, et al. Regulation of cellular proliferation and intimal formation following balloon injury in arthrosclerotic rabbit arteries. J Clin Invest 1996;98:225-235.
101. Steg PG, Tahlil O, Aubailly N, et al. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997; 96:408-411.
102. Harrell RL, Rajanayagam S, Doanes AM, et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 1997;96:621-627.
103. Bonini C, Ferrari G, Verzeletti S, et al. HSY-tk gene transfer into donor lymphocytes for control of allogeneic gratf-versus-leukemia. Science 1997;276: 1719-1724.
104. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5283.
105. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
106. Chang MW, Barr W, Lu MM, et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260-2268.
107. Schwartz LB, Moawad J, Svensson EC, et al. Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg 1999;29: 874-881.
108. kipl, an inhibitor of neointima formation in the rat carotid artery. J Clin Invest 1997;99:2334-2341.
109. Yonemitsu Y, Kaneda Y, Tanaka S, et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998;82:147-156.
110. Maillard L, van Belle E, Smith RC, et al. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res 1997;35:536-546.
111. Shi Y, Fard A, Galeo A, et al. Cellular, molecular, biological, and immunological research: transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994;90:944-951.
112. Gunn J, Holt CM, Francis SE, et al. The effect of oligonucleotidcs to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res 1997;80:520-531.
113. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8478.
114. Hanna AK, Fox JC, Neschis DG, et al. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surq 1997;25:320-325.
115. Zhu NL, Wu L, Liu PX, et al. Downregulation of cyclin Gl expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997;96:628-635.
116. Ueno H, Yamamoto H, Ito S, et al. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol 1997;17:898-904.
117. Asahara T, Bauters C, Pastore G, et al. Molecular and cellular cardiology: local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793-2801.
118. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
119. Veit K, Boissel JP, Buerke M, et al. Highly efficient liposome-mediated gene transfer of inducible nitric oxide synthese in vivo and in vitro in vascular smooth muscle cells. Cardiovasc Res 1999;43:808-822.
120. Chen L, Daum G, Forough R, et al. Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells in balloon-injured carotid artery. Circ Res 1998;82:862-870.
121. Shears LL, Kibbe MR, Murdock A, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
122. Varenne O, Pislaru S, Gillijns H, Pelt NV, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998;98:919-926.
123. Santiago FS, Lowe HC, Kavurma MM, et al. New DNA enzyme targeting Egr-l mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999;5:1264-1269.
124. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASER J 1999;13:9-22.
125. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93:662-670.
126. Takeshita S, Tsurumi Y, Couffinahl T, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996;75:487-501.
127. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
128. Mack CA, Magovern CJ, Budenbender KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998;27:699-709.
129. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000;6:405-413.
130. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.
131. Kanno S, Oda N, Abe M, et al. Establishment of a simple and practical procedure applicable to therapeutic angiogenesis. Circulation 1999;99:2682-2687.
132. Pepper MS, Ferrara N, Orci L, et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;3:211-220.
133. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-630.
134. Schumacher MD, Pecher MD, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650.
135. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-l, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-1180.
136. Shyu K-G, Manor O, Magner M, et al. Direct intramuscular injection of plasmid DNA encoding angiopoietin-l but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998;98:2081-2087.
137. Aoki M, Morishita R, Taniyama Y, et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: upregulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000;7:417-427.
138. Acton SL, Kozarsky KF, Rigotti A. The HDL receptor SR-BI: a new therapeutic target for atherosclerosis? Mol Med Today 1999;5:518-524.
139. Paszty C, Maeda N, Verstuyft J, et al. Apolipoprotein A1 transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899-903.
140. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607-9611.
141. de Geest B, Zhao Z, Collen D, et al. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation 1998;98:2081-2087.
142. Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human apo A-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99:105-110.
143. Hoeg JM, Santamarina-Fojo S, Berard AM, et al. Overexpression of lecithin: cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996;93:11448-11453.
144. Kozarsky KF, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387:414-417.
145. Fan L, Owen JS, Dickson G. Construction and characterisation of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferasc. Atherosclerosis 1999; 147:139-145.
146. Giannoukakis N, Thomson A, Robbins P. Gene therapy in transplantation. Gene Ther 1999;6:1499-1511.
147. Bracy JL, Sach DL, Iacomini J. Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science 1998;281:1845-1847.
148. Poston AS, Mann MJ, Hoyt EG, et al. Antisense oligonucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. Transplant 1999;68:825-832.
149. Braunberger E, Raynal-Raschilas N, Thomas-Vaslin V, et al. Tolerance induced without immunosuppression in a T-lymphocyte suicide-gene therapy cardiac allograft model in mice. J Thorac Cardiovasc Surg 2000;119: 46-51.
150. 2-adrenergic receptor gene delivery. J Clin Invest 1999;104:21-29.
151. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA 2a. Circulation 1999;100:2308-2311.
152. Zoldhelyi P, McNatt J, Xu X-M, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of the cyclooxygenase gene. Circulation 1996; 93:10-17.
153. Carmeliet P, Moons L, Dewerchin M, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor, and the plasminogen system. Ann NY Acad Sci 1997;811:191-206.
154. Tang X, Mohuczy D, Zhang YC, et al. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. Am J Phys 1999;277:H2392-H2399.
155. Das DK, Engelman RM, Maulik N, et al. Molecular targets of gene therapy. Ann Thorac Surg 1999;68:1929-1933.
156. Giordano FJ, Ping P, McKirnan MD. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-539.
157. Sakuraba H, Yanagawa Y, Igarashi T, et al. Cardiovascular manifestations in Fabry's disease. Clin Genet 1986;29:276-283.
158. Barr E, Leiden JM. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 1991;254:1507-1509.
159. Rosenberg LE, Schechter AN. Gene therapist, heal thyself. Science 2000;287:1751.
160. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
161. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362-367.
162. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
163. Harrington JJ, Van Bokkelen G, Mays RW, et al. Formation of de novo centromeres and construction of first-generation human artificial microchromosomes. Nat Genet 1997;15:345-354.
164. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science 1999;285:2084-2088.